A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients
Sponsor: Firas El Chaer, MD
Terminated
Slow accrual
Other Hematologic Malignancy trials with similar outcome
This EARLY_PHASE1 trial investigates Hematologic Malignancy and Platelet Refractoriness and is currently terminated or withdrawn. Firas El Chaer, MD leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated EARLY_PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
Status: Recruiting → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
-
Feb 2023 — Sep 2023 [monthly]
Recruiting EARLY_PHASE1
▶ Show 3 earlier versions
-
Dec 2022 — Feb 2023 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Dec 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Apr 2022 — Jun 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Firas El Chaer, MD
For direct contact, visit the study record on ClinicalTrials.gov .